Ménière's DiseasePhase 1PK-BesTNCT05938517
Pharmacokinetic Profile of Betahistine With and Without Selegiline in Healthy Volunteers
A Phase 1 study testing Betahistine dihydrochloride and Selegiline-hydrochloride in people with Ménière's Disease, run by Ludwig-Maximilians - University of Munich at 1 site in Germany.
Trial summary
The goal of this pharmakokinetic trial is to demonstrate that Betahistine serum concentration is higher after combination treatment with Betahistine and Selegiline compared to Betahistine alone. Read more about this study
- Who is it for?
- Ages 18 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Ménière's Disease
- What is being tested?
- Betahistine dihydrochloride and Selegiline-hydrochloride
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 15 participants
- Where
- 1 siteGermany
- Study dates
- 2 Jun 2021to 14 Oct 2021
- Phase
- Phase 1
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Diagnosis and main criteria for inclusion:
- Adult healthy volunteers, males and non-pregnant, non-breastfeeding woman with adequate contraception
- Subjects must meet all of the following inclusion criteria to be eligible for enrolment into the trial:
- Healthy volunteers (age ≥ 18 years and ≤ 70 years) as determined by screening
- and Principal Investigator's judgement
- No intake of medication due to an illness
- Written informed consent of the subject
- Systolic blood pressure between 90 and 140 mmHg and diastolic blood pressure between 60 and 90 mmHg at screening
- PQ interval in the ECG between 0.12 s and 0.20 s
- Duration of the QRS complex between 0.06 s and 0.10 s
- QTc interval 440 ms or less
- Heart rate between 60 and 100 beats per minute
- Subjects with the ability to follow study instructions and likely to attend and complete all required visits
Subjects presenting with any of the following exclusion criteria were not included in the trial:
- Subject is not able to give consent
- A condition in which repeated serum draws or injections pose more than minimal risk for the subjects, such as haemophilia, other severe coagulation disorders or significantly impaired venous access
- Participation in another study with an investigational drug or device within the last 30 days, prior participation in the present study, or planned participation in another trial
- Intake of medication due to an illness
- Subjects with a physical or psychiatric condition which at the investigator's discretion may put the subject at risk, may confound the trial results, or may interfere with the subject's participation in the clinical trial before participation in this study
- Current or planned pregnancy or breastfeeding woman
- Woman of childbearing potential who is not willing to use medically reliable methods of contraception for the entire study duration
- Intake of alcohol 24 hours before first IMP intake or during study participation
- Known or persistent abuse of medication, drugs or alcohol (positive test for alcohol or drugs)
- Known contraindications for Betahistine, such as bronchial asthma, pheochromocytoma, treatment with antihistaminic drugs, ulcer of the stomach or duodenum, severe dysfunction of liver or kidney, hypersensitivity to Betahistine or other ingredients
- Known contraindications for Selegiline, e.g. use of opioids, tricyclic antidepressants, sympathomimetics, non-selective MAOIs, (selective) serotonin (-noradrenaline) re-uptake inhibitors (SSRI/SNRI), serotonin agonists, hypersensitivity to Selegiline or other ingredients
- Hereditary intolerance to galactose, hereditary deficiency of lactose, glucose-galactose-malabsorption
- AV Block in the ECG
- Hypotonic or hypertonic subjects according to the criteria of the National Heart, Lung and Serum Institute (Hypertension > 90/140 mmHg, Hypotension < 90/60 mmHg)
Trial locations and contacts
1 site in 1 country.
Germany1 site
Department of Neurology, Ludwig Maximilian University
Munich, Bavaria, 81377
About this study
Official title: Pharmacokinetic Profile of Betahistine Serum Concentration With and Without Selegiline in Healthy Volunteers - a Prospective Mono-center Open-labeled Phase I Trial ("PK-BeST")
The goal of this pharmakokinetic trial is to demonstrate that Betahistine serum concentration is higher after combination treatment with Betahistine and Selegiline compared to Betahistine alone.
The main questions it aims to answer are:
Read more
Is the plasma concentration of betahistine higher due to combination treatment with selegiline compared to betahistine monotherapy? How is the safety of the combination treatment with betahistine and selegiline, the pharmacokinetics of betahistine in different dosages in blood, and the inter-individual differences in the metabolism?
Subjects satisfying all selection criteria will receive three different dosages of Betahistine alone orally in ascending order (24 mg, 48 mg, 96 mg) in the first period. In the second period, subjects received Betahistine treatment as described for first period but after pre- and continuous treatment with 5 mg/ml Selegiline orally. Plasma concentration (namely the AUC0-240min) of betahistine will be measured before and 10, 30, 60, 90, 120, 180, 240 minutes after treatment with blood examinations. Safety parameters include assessment of adverse events, ECG, vital signs, laboratory measurements including kidney and liver function, full blood count and pregnancy and drug screening test.
Read the detailed description
This study was an investigator-initiated (IIT) prospective mono-center open-labeled trial to demonstrate that Betahistine serum concentration is higher after combination treatment with Betahistine and Selegiline compared to Betahistine alone in healthy subjects.
Subjects were screened for their eligibility to participate in the study. Each subject gave written informed consent before any study-related procedures were performed.
Subjects satisfying all selection criteria were included in the open-labeled trial receiving 3 different dosages of Betahistine alone in ascending order (24 mg, 48 mg, 96 mg) in the first period. In the second period, subjects received Betahistine treatment as described for first period but after pre- and continuous treatment with 5 mg/ml Selegiline. Betahistine serum concentrations were measured over a period of 240 min at 8 time points (area under the curve, AUC0-240 min). Safety parameters included assessment of adverse events, ECG, vital signs, laboratory measurements including kidney and liver function, full blood count and pregnancy and drug screening test). Safety monitoring was conducted during every visit and assessment of vital parameter and adverse events were conducted 10, 30, 60, 90, 120, 180, and 240min after betahistine intake. The clinical trial was conducted in a hospital of maximum care with the possibility to consult a specialist for possible symptoms of an intoxication especially an anesthesiologist, cardiologist and neurologist 24 hours/7 days a week.
- Conditions
- Ménière's Disease
- Being tested
- Betahistine dihydrochloride, Selegiline-hydrochloride
- Keywords
- Betahistine-dihydrochloride, Selegiline-hydrochloride, MAO-B inhibitor
- Medical subject headings
- Meniere Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Betahistine dihydrochlorideDrug
Also called Vasomotal
Each subject received single dosages of Betahistine (24 mg, 48 mg, 96 mg) for pharmacokinetic serum draw with at least two days between the different dosages.
Selegiline-hydrochlorideDrug
Also called Selegiline-neuraxpharm
In the second period, each subject was pre-treated with Selegiline (5 mg/day) for one week and treated continuously with Selegiline (5 mg/day) in combination with the single dosages of Betahistine (24 mg, 48 mg, 96 mg) with at least two days between the different dosages.
| Study group | Role | What they receive |
|---|---|---|
| Betahistine-dihydrochloride | Experimental | Subjects received single dosages of Betahistine (24 mg, 48 mg, 96 mg) orally for pharmacokinetic serum draw with at least two days between the different dosages. Receives: Drug: Betahistine dihydrochloride |
| Betahistine-dihydrochloride and Selegiline-hydrochloride | Experimental | Subjects were pre-treated with Selegiline (5 mg/day) orally for one week and treated continuously with Selegiline (5 mg/day) in combination with the single dosages of Betahistine (24 mg, 48 mg, 96 mg) orally with at least two days between the different dosages. Receives: Drug: Betahistine dihydrochloride; Drug: Selegiline-hydrochloride |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean AUC of Betahistine
Mean AUC of Betahistine in serum after treatment of Betahistine alone or with Selegiline
Measured: 240 minutes
Secondary outcomes (2)
Mean Half Life of Betahistine
Half Life of Betahistine following the administration of different Betahistine doses with and without Selegiline
Measured: 240 minutes
Occurrence of adverse effects
Occurrence of adverse effects following the administration of different Betahistine doses with and without Selegiline
Measured: up to 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jul 2023
- Study start2 Jun 2021
- Primary completion14 Oct 2021
- Study completion14 Oct 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Ménière's DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Crossover
- Model description
- Subjects satisfying all selection criteria were included in the open-labeled trial receiving 3 different dosages of Betahistine alone in ascending order (24 mg, 48 mg, 96 mg) in the first period. In the second period, subjects received Betahistine treatment as described for first period but after pre- and continuous treatment with 5 mg/ml Selegiline.
- Masking
- None (open label)
- Enrolment
- 15 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ludwig-Maximilians - University of Munich
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Prof. Dr. med. Michael Strupp, Ludwig-Maximilians - University of Munich
- Investigators
- Michael Strupp, M.D., Principal investigator, LMU Munich
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05938517
- Sponsor's protocol ID
- 19-0992 fed
- Acronym
- PK-BesT
- Status last verified
- Jul 2023
- First submitted
- 26 Jun 2023
- Last updated
- 12 Jul 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Strupp M, Churchill GC, Naumann I, Mansmann U, Al Tawil A, Golentsova A, Goldschagg N. Examination of betahistine bioavailability in combination with the monoamine oxidase B inhibitor, selegiline, in humans-a non-randomized, single-sequence, two-period titration, open label single-center phase 1 study (PK-BeST). Front Neurol. 2023 Oct 18;14:1271640. doi: 10.3389/fneur.2023.1271640. eCollection 2023.
PubMed 37920833